生物试剂研发与销售
Search documents
康为世纪: 关于预计2025年度日常关联交易的公告
Zheng Quan Zhi Xing· 2025-08-29 17:12
Core Viewpoint - The announcement details the expected daily related transactions for Jiangsu Kangwei Century Biotechnology Co., Ltd. in 2025, emphasizing that these transactions are necessary for normal business operations and will not adversely affect the company's ongoing viability or independence [1][8]. Group 1: Daily Related Transactions Overview - The board of directors approved the expected daily related transactions for 2025 during meetings held on August 27, 2025, with non-related directors and all supervisors voting in favor [1]. - The transactions are based on normal production and operational needs, adhering to fair and equitable pricing principles [1][7]. Group 2: Expected Amounts and Categories - The expected transaction amounts for 2025 include purchasing raw materials for 15 million yuan and providing labor services for 2 billion yuan [3][4]. - The total expected amount for related transactions is 2.84 billion yuan, with specific categories including vehicle leasing, office space leasing, property management, and technical services [4][6]. Group 3: Related Parties and Relationships - The related parties include Shanghai Tianhao Biotechnology Co., Ltd., which holds a 49% stake in a subsidiary, and Beijing Kangwei, the controlling shareholder of the company [5][6]. - The company maintains a stable cooperative relationship with these related parties, ensuring ongoing transactions [8]. Group 4: Pricing Policies and Agreements - The pricing for related transactions is determined based on market principles, ensuring fairness and non-detriment to the company and its shareholders [7]. - Contracts or agreements will be signed with related parties based on the specific business needs following board approval [7][8]. Group 5: Necessity and Impact of Related Transactions - The expected related transactions are deemed necessary for the company's stable operations and business development, enhancing market competitiveness [7][8]. - The company asserts that these transactions will not lead to dependency on related parties and will not harm the interests of shareholders, particularly minority shareholders [7][8].